Logo image of BHTG

BIOHITECH GLOBAL INC (BHTG) Stock Fundamental Analysis

NASDAQ:BHTG - Nasdaq - Common Stock

0.837  -0.01 (-1.54%)

After market: 0.837 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BHTG. BHTG was compared to 84 industry peers in the Commercial Services & Supplies industry. BHTG may be in some trouble as it scores bad on both profitability and health. BHTG is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year BHTG has reported negative net income.
BHTG Yearly Net Income VS EBIT VS OCF VS FCFBHTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -5M -10M

1.2 Ratios

Industry RankSector Rank
ROA -14.64%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BHTG Yearly ROA, ROE, ROICBHTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 200 -200 400

1.3 Margins

Industry RankSector Rank
OM -54.81%
PM (TTM) -60.71%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHTG Yearly Profit, Operating, Gross MarginsBHTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -100 -200 -300 -400

0

2. Health

2.1 Basic Checks

The number of shares outstanding for BHTG has been increased compared to 1 year ago.
BHTG has a worse debt/assets ratio than last year.
BHTG Yearly Shares OutstandingBHTG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M
BHTG Yearly Total Debt VS Total AssetsBHTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M 50M

2.2 Solvency

BHTG has an Altman-Z score of -1.97. This is a bad value and indicates that BHTG is not financially healthy and even has some risk of bankruptcy.
BHTG has a Debt/Equity ratio of 5.04. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 5.04
Debt/FCF N/A
Altman-Z -1.97
ROIC/WACCN/A
WACCN/A
BHTG Yearly LT Debt VS Equity VS FCFBHTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 0.42 indicates that BHTG may have some problems paying its short term obligations.
BHTG has a Quick Ratio of 0.42. This is a bad value and indicates that BHTG is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.42
Quick Ratio 0.37
BHTG Yearly Current Assets VS Current LiabilitesBHTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 5M 10M 15M

7

3. Growth

3.1 Past

BHTG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.59%, which is quite impressive.
The Revenue has grown by 208.64% in the past year. This is a very strong growth!
BHTG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.24% yearly.
EPS 1Y (TTM)35.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)208.64%
Revenue growth 3Y34.44%
Revenue growth 5Y31.24%
Sales Q2Q%511.26%

3.2 Future

The Earnings Per Share is expected to grow by 11.11% on average over the next years. This is quite good.
The Revenue is expected to grow by 53.86% on average over the next years. This is a very strong growth
EPS Next Y46.66%
EPS Next 2Y24.68%
EPS Next 3Y22.58%
EPS Next 5Y11.11%
Revenue Next Year160.6%
Revenue Next 2Y59.88%
Revenue Next 3Y66.05%
Revenue Next 5Y53.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BHTG Yearly Revenue VS EstimatesBHTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BHTG Yearly EPS VS EstimatesBHTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4 -0.5

1

4. Valuation

4.1 Price/Earnings Ratio

BHTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BHTG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHTG Price Earnings VS Forward Price EarningsBHTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -11.32
BHTG Per share dataBHTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as BHTG's earnings are expected to grow with 22.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y22.58%

0

5. Dividend

5.1 Amount

No dividends for BHTG!.
Industry RankSector Rank
Dividend Yield N/A

BIOHITECH GLOBAL INC

NASDAQ:BHTG (12/10/2021, 8:56:33 PM)

After market: 0.837 0 (0%)

0.837

-0.01 (-1.54%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners18.58%
Ins Owner Change0%
Market Cap23.84M
Analysts82.22
Price Target3.57 (326.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.76
P/FCF N/A
P/OCF N/A
P/B 4.17
P/tB N/A
EV/EBITDA -11.32
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.47
BVpS0.2
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.64%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -54.81%
PM (TTM) -60.71%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 5.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.42
Quick Ratio 0.37
Altman-Z -1.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y46.66%
EPS Next 2Y24.68%
EPS Next 3Y22.58%
EPS Next 5Y11.11%
Revenue 1Y (TTM)208.64%
Revenue growth 3Y34.44%
Revenue growth 5Y31.24%
Sales Q2Q%511.26%
Revenue Next Year160.6%
Revenue Next 2Y59.88%
Revenue Next 3Y66.05%
Revenue Next 5Y53.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A